Shalini Andersson, PhD

Chief Scientist and Head of Oligonucleotide Discovery
AstraZeneca/Discovery Sciences

Read More

Isabel Aznarez, PhD

 

Co-founder & VP, Discovery Research
Stoke Therapeutics

Read More

Annabelle Biscans, PhD

Associate Principal Scientist
AstraZeneca R&D

Read More

Masad J. Damha, PhD, FCIC

 

Distinguished James McGill Professor
McGill University

Read More

Bruno Miguel da Cruz Godinho, PhD

 

 

Scientist
Atalanta Therapeutics

Read More

Maja Janas De Angelis, PhD, DABT

Director
Alnylam Pharmaceuticals

Read More

Martin Maier, PhD

SVP, Research
Alnylam Pharmaceuticals

Read More

Rebecca R. Miles, PhD

Principal Research Scientist
Lilly Research Labs, Indianapolis, IN

Read More

Laura Sepp-Lorenzino, PhD

Chief Scientific Officer
Intellia Therapeutics

Read More

Bruce A. Sullenger, PhD

Professor
Department of Surgery, Duke University

Read More

Marie Wikström Lindholm, PhD

 

SVP, Head of Molecular Design
Silence Therapeutics

Read More

Takanori Yokota,MD, PhD

 

Professor of Department Neurology
Tokyo Medical and Dental University

Read More

Timothy Yu, MD, PhD

Associate Professor
Harvard Medical School

Read More

Current OTS members are encouraged to participate in the BOD election which will be open through December 12, 2021.  All current members have been emailed a link to the ballot which can also be reached here.

If you did not receive the email or have questions about the status of your membership, contact us at info@oligotherapeutics.org.